Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases.

ABSTRACT: Plasma exchange (PE) and immunoadsorption (IA) are frequently used for treatment of various autoimmune-mediated neurological diseases, including multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain-Barré syndrome (GBS). Although both methods are generally regarded as well-tolerated treatment options, evidence for safety and tolerability is low for most indications and largely relies on small case series. In this study, we retrospectively analysed adverse events (AEs) and laboratory changes in 284 patients with various neurological indications who received either PE (n = 65, 113 cycles) or IA (n = 219, 435 cycles) between 2013 and 2020 in our Neurology department. One standard treatment cycle for PE as well as IA consisted of five treatments on fiv

SUBMITTER: Dorst J 

PROVIDER: S-EPMC7565027 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature